Videos

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Lau discusses the importance of developing and applying technology to predict potential adverse cardiovascular outcomes in pregnant patients.

At ACAAI 2025, Adatia discussed interim KONFIDENT-KID trial findings showing oral sebetralstat safely reduced symptom burden in pediatric HAE.

Gatti highlights the role of social media in dermatology, noting its importance for business growth but emphasizing the need to focus on education.

At ACAAI 2025, Harris spoke with HCPLive about Excellergy’s ECRI program, exploring IgE modulation, safety goals, and potential long-term effects in CSU.

Alkhouri breaks down recent therapeutic progress in MASH and explains new data on resmetirom’s use in patients with compensated MASH cirrhosis.

Weir pointed out that significant benefits were seen with concurrent SGLT2 inhibitor use.

Kremer breaks down new data on the disease-modifying and symptom-relieving effects of seladelpar presented at AASLD The Liver Meeting 2025.

GLISTEN AASLD-presented data show linerixibat reduces biomarkers and itch in PBC, supporting the drug as an ileal bile acid transporter inhibitor.

Strnad emphasizes the promise offered by RNA therapeutics in liver disease and what potential fazirsiran may hold for AATD liver disease in a broad spectrum of patients.

At ACAAI 2025, Harris discussed research on novel mechanism known as allergic effector cell response inhibitors.

Younossi explains the importance of patient-reported outcomes and assessing HRQoL, breaking down findings from an analysis of the MAESTRO-NAFLD trial of resmetirom.

Kremer describes recent advancements in the PBC treatment landscape and reviews findings from abstracts on elafibranor presented at AASLD The Liver Meeting 2025.

McGill emphasizes new exciting data shared at ACR 2025.

ALTUS findings presented at AASLD show mt-HBT detects early-stage HCC with >66% higher sensitivity than ultrasound, addressing gaps in liver cancer surveillance.

In a phase 3 NATRON trial presented at ACAAI 2025, Ogbogu discussed how benralizumab reduced flare in patients with hypereosinophilic syndrome.

In this segment of his SDPA Fall interview, Nguyen highlighted his second talk ‘Patterns in Red and Purple: Decoding Vasculitis in the Skin.’

AASLD-presented data show HCCs persist after weight or diabetes control, with a new target of fibrotic immune phenotype to prevent MASH-related complications.

At ACAAI 2025, Golden discussed how mild local reactions and expected systemic effects support the sublingual film’s strong safety profile in children.

McLaughlin discussed the previous ZENITH, PULSAR, and STELLAR trials, and how this pooled cohort analysis emphasizes sotatercept’s impressive efficacy.

This interview features Nguyen discussing his SDPA talk titled ‘The Itch Within: Immune Pathways Driving Chronic Spontaneous Urticaria.’

Children achieved therapeutic epinephrine levels within 2 minutes on AQST-109 (Anaphylm), showing an early cardiovascular response similar to adults.

Data presented at AASLD 2025 hepatitis delta patients experience significant physical and emotional challenges, emphasizing the need for holistic care approaches and screening beyond risk-based recommendations.

At ACAAI 2025, Gross outlined new food allergy ICD-10 codes, clarified documentation rules, and shared tips to help allergists prevent claim denials.

In this segment of his interview, Abbas highlights when to refer a patient for systemic macrocytosis to a hematology or mast cell disease specialist.

HCPLive spoke with Al Ali at ACAAI 2025 about a study comparing the safety of protocols for milk and peanut allergens.

Katzenstein reviews noninvasive tests used for MASH and explains her research on the ELF test’s real-world potential for predicting liver stiffness.

This interview was on-site at SDPA, featuring a discussion of the tools needed to identify systemic macrocytosis.